Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 74 of the 74 references it cites were found in a registry or an index.

Intracellular inflammatory and antioxidant pathways in postmortem frontal cortex of subjects with major depression: effect of antidepressants

Open access
Martín-Hernández, David, Caso, Javier R., Javier Meana, J., Callado, Luis F., Madrigal, José L. M., García-Bueno, Borja, Leza, Juan C. · 2018 · Journal of Neuroinflammation

Abstract

BACKGROUND: Studies show that Toll-like receptors (TLRs), members of the innate immune system, might participate in the pathogenesis of the major depressive disorder (MDD). However, evidence of this participation in the brain of patients with MDD has been elusive. METHODS: This work explores whether the protein expression by immunodetection assays (Western blot) of elements of TLR-4 pathways controlling inflammation and the oxidative/nitrosative stress are altered in postmortem dorsolateral prefrontal cortex of subjects with MDD. The potential modulation induced by the antidepressant treatment on these parameters was also assessed. Thirty MDD subjects (15 antidepressant-free and 15 under antidepressant treatment) were matched for gender and age to 30 controls in a paired design. RESULTS: No significant changes in TLR-4 expression were detected. An increased expression of the TLR-4 endogenous ligand Hsp70 (+ 33%), but not of Hsp60, and the activated forms of mitogen-activated protein kinases (MAPKs) p38 (+ 47%) and JNK (+ 56%) was observed in MDD. Concomitantly, MDD subjects present a 45% decreased expression of DUSP2 (a regulator of MAPKs) and reduced (- 21%) expression of the antioxidant nuclear factor Nrf2. Antidepressant treatment did not modify the changes detected in the group with MDD and actually increased (+ 25%) the expression of p11, a protein linked with the transport of neurotransmitters and depression. CONCLUSION: Data indicate an altered TLR-4 immune response in the brain of subjects with MDD. Additional research focused on the mechanisms contributing to the antidepressant-induced TLR-4 pathway modulation is warranted and could help to develop new treatment strategies for MDD.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1186/s12974-018-1294-2

Cites

74 of 74 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig. 1 Effects of MDD and antidepressant treatment on the expression of TLR-4 and its endogenous ligands Hsp60 and Hsp70. There were no differences in the protein expression of TLR-4 among controls and subjects with MDD (a, b). There were no statistical differences between groups in the protein expression values of Hsp60 (c, d). Subjects with MDD showed a significant 33% increase in the Hsp70 protein expression compared with controls (e). The statistical significance disappeared when the AD-free at death and the AD-treated groups were split, but both groups maintained a trend to show higher values than control group (f). The densitometric data of the band of interest were normalized by beta-actin. Some blots were cropped (black lines) for improving the clarity and conciseness of the presentation. Data are means ± SEM; *p < 0.05 vs. control; unpaired two-tailed t test was performed when comparing controls vs MDD. One-way ANOVA with a Fisher’s LSD post hoc test was used to compare between controls and AD-free and AD-treated MDD groups. See the “Chemicals and statistical analyses” section for more details
Fig. 1 Effects of MDD and antidepressant treatment on the expression of TLR-4 and its endogenous ligands Hsp60 and Hsp70. There were no differences in the protein expression of TLR-4 among controls and subjects with MDD (a, b). There were no statistical differences between groups in the protein expression values of Hsp60 (c, d). Subjects with MDD showed a significant 33% increase in the Hsp70 protein expression compared with controls (e). The statistical significance disappeared when the AD-free at death and the AD-treated groups were split, but both groups maintained a trend to show higher values than control group (f). The densitometric data of the band of interest were normalized by beta-actin. Some blots were cropped (black lines) for improving the clarity and conciseness of the presentation. Data are means ± SEM; *p < 0.05 vs. control; unpaired two-tailed t test was performed when comparing controls vs MDD. One-way ANOVA with a Fisher’s LSD post hoc test was used to compare between controls and AD-free and AD-treated MDD groups. See the “Chemicals and statistical analyses” section for more detailsCC BY · PubMed Central
Fig. 2 Effects of MDD and antidepressant treatment on the expression of MAPKs and on the expression of the MAPK activity regulator DUSP2. When considering the phosphorylated forms of the proteins, p-ERK1/2, p-JNK, and the ratio between p-p38/total p38 were clearly higher in MDD than in controls (a, c, e). The expression values were selectively increased in AD-treated subjects (b, d, f). Analysis of covariance controlling for BMI did not modify p-p38/total p38 ratio results. DUSP2 expression was decreased in MDD compared with matched controls (g), and this statistical difference appeared both in the subjects AD-free at time of death and in AD-treated subjects when compared with controls (h). The densitometric data of the band of interest were normalized by beta-actin. Some blots were cropped (black lines) for improving the clarity and conciseness of the presentation. Data are means ± SEM; *p < 0.05, **p < 0.01 vs. control; unpaired two-tailed t test was performed when comparing controls vs MDD. One-way ANOVA with a Fisher’s LSD post hoc test was used to compare between controls and AD-free and AD-treated MDD groups. See the “Chemicals and statistical analyses” section for more details
Fig. 2 Effects of MDD and antidepressant treatment on the expression of MAPKs and on the expression of the MAPK activity regulator DUSP2. When considering the phosphorylated forms of the proteins, p-ERK1/2, p-JNK, and the ratio between p-p38/total p38 were clearly higher in MDD than in controls (a, c, e). The expression values were selectively increased in AD-treated subjects (b, d, f). Analysis of covariance controlling for BMI did not modify p-p38/total p38 ratio results. DUSP2 expression was decreased in MDD compared with matched controls (g), and this statistical difference appeared both in the subjects AD-free at time of death and in AD-treated subjects when compared with controls (h). The densitometric data of the band of interest were normalized by beta-actin. Some blots were cropped (black lines) for improving the clarity and conciseness of the presentation. Data are means ± SEM; *p < 0.05, **p < 0.01 vs. control; unpaired two-tailed t test was performed when comparing controls vs MDD. One-way ANOVA with a Fisher’s LSD post hoc test was used to compare between controls and AD-free and AD-treated MDD groups. See the “Chemicals and statistical analyses” section for more detailsCC BY · PubMed Central
Fig. 3 Effects of MDD and antidepressant treatment on the antioxidant nuclear factor (erythroid 2-derived)-like 2 (Nrf2) pathway. Subjects with MDD presented a non-significant trend to decrease (− 18%) the Nrf2 activator PI3K expression when compared with controls, being the decrease in the expression more pronounced in the AD-treated group (a, b). Subjects AD-free and AD-treated at death showed a non-significant trend towards a 16–18% increase in the expression of the cytoplasmatic inhibitor of Nrf2 Keap-1 protein when compared with controls (c, d). Subjects with MDD showed a significant decreased nuclear expression of Nrf2 (e). AD-treated group showed a decreased nuclear expression of Nrf2 compared with controls (f). The densitometric data of the band of interest were normalized by beta-actin or GAPDH for the cytoplasmic or nuclear fractions, respectively. Some blots were cropped (black lines) for improving the clarity and conciseness of the presentation. Data are means ± SEM; *p < 0.05 vs. control; unpaired two-tailed t test was performed when comparing controls vs MDD. One-way ANOVA with a Fisher’s LSD post hoc test was used to compare between controls and AD-free and AD-treated MDD groups. See the “Chemicals and statistical analyses” section for more details
Fig. 3 Effects of MDD and antidepressant treatment on the antioxidant nuclear factor (erythroid 2-derived)-like 2 (Nrf2) pathway. Subjects with MDD presented a non-significant trend to decrease (− 18%) the Nrf2 activator PI3K expression when compared with controls, being the decrease in the expression more pronounced in the AD-treated group (a, b). Subjects AD-free and AD-treated at death showed a non-significant trend towards a 16–18% increase in the expression of the cytoplasmatic inhibitor of Nrf2 Keap-1 protein when compared with controls (c, d). Subjects with MDD showed a significant decreased nuclear expression of Nrf2 (e). AD-treated group showed a decreased nuclear expression of Nrf2 compared with controls (f). The densitometric data of the band of interest were normalized by beta-actin or GAPDH for the cytoplasmic or nuclear fractions, respectively. Some blots were cropped (black lines) for improving the clarity and conciseness of the presentation. Data are means ± SEM; *p < 0.05 vs. control; unpaired two-tailed t test was performed when comparing controls vs MDD. One-way ANOVA with a Fisher’s LSD post hoc test was used to compare between controls and AD-free and AD-treated MDD groups. See the “Chemicals and statistical analyses” section for more detailsCC BY · PubMed Central
Fig. 4 Effects of MDD and AD treatment on the expression of S100A10 (p11) and NF-κB. There were no significant differences in the p11 expression between control and MDD groups (a). p11 was elevated in the AD-treated at death group compared with the AD-free at death and the control groups (b). The p65 subunit of the transcription factor NF-κB expression was decreased in patients with MDD compared with controls (c) and when AD-free and AD-treated at death groups were compared with matched controls (d). The densitometric data of the band of interest were normalized by beta-actin or GAPDH for the cytoplasmatic or nuclear fractions, respectively. Some blots were cropped (black lines) for improving the clarity and conciseness of the presentation. Data are means ± SEM; *p < 0.05, **p < 0.01 vs. control; #p < 0.05 vs. AD-free; unpaired two-tailed t test was performed when comparing controls vs MDD. One-way ANOVA with a Fisher’s LSD post hoc test was used to compare between controls and AD-free and AD-treated MDD groups. See the “Chemicals and statistical analyses” section for more details
Fig. 4 Effects of MDD and AD treatment on the expression of S100A10 (p11) and NF-κB. There were no significant differences in the p11 expression between control and MDD groups (a). p11 was elevated in the AD-treated at death group compared with the AD-free at death and the control groups (b). The p65 subunit of the transcription factor NF-κB expression was decreased in patients with MDD compared with controls (c) and when AD-free and AD-treated at death groups were compared with matched controls (d). The densitometric data of the band of interest were normalized by beta-actin or GAPDH for the cytoplasmatic or nuclear fractions, respectively. Some blots were cropped (black lines) for improving the clarity and conciseness of the presentation. Data are means ± SEM; *p < 0.05, **p < 0.01 vs. control; #p < 0.05 vs. AD-free; unpaired two-tailed t test was performed when comparing controls vs MDD. One-way ANOVA with a Fisher’s LSD post hoc test was used to compare between controls and AD-free and AD-treated MDD groups. See the “Chemicals and statistical analyses” section for more detailsCC BY · PubMed Central
Fig. 5 Schematic representation of the pathways being affected by MDD and by treatments. Inflammatory pathway studied (a) and results obtained (b). In b, the colors show the statistically significant changes in major depressive disorder (MDD) vs. control group (red = upregulation, blue = downregulation). The arrows indicate the effects on the MDD group treated with antidepressants at time of death (AD-treated group). TLR Toll-like receptor, Hsp Heat shock protein, MyD88 myeloid differentiation primary response 88, MKK mitogen-activated protein kinase kinase, ERK extracellular signal-regulated kinase, JNK c-Jun N-terminal kinase, p38 protein 38, NF-κB nuclear factor kappa B, 5-HTR serotonin receptor, p11 S100 calcium-binding protein A10 (S100A10), DUSP2 dual-specificity phosphatase 2, Nrf2 nuclear factor (erythroid 2-derived)-like 2, Keap-1 Kelch-like ECH-associated protein 1, PI3K phosphoinositide 3-kinase, P phosphate
Fig. 5 Schematic representation of the pathways being affected by MDD and by treatments. Inflammatory pathway studied (a) and results obtained (b). In b, the colors show the statistically significant changes in major depressive disorder (MDD) vs. control group (red = upregulation, blue = downregulation). The arrows indicate the effects on the MDD group treated with antidepressants at time of death (AD-treated group). TLR Toll-like receptor, Hsp Heat shock protein, MyD88 myeloid differentiation primary response 88, MKK mitogen-activated protein kinase kinase, ERK extracellular signal-regulated kinase, JNK c-Jun N-terminal kinase, p38 protein 38, NF-κB nuclear factor kappa B, 5-HTR serotonin receptor, p11 S100 calcium-binding protein A10 (S100A10), DUSP2 dual-specificity phosphatase 2, Nrf2 nuclear factor (erythroid 2-derived)-like 2, Keap-1 Kelch-like ECH-associated protein 1, PI3K phosphoinositide 3-kinase, P phosphateCC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 74 references

Cited by

See all 80

Metadata

Authors
Martín-Hernández, D., Caso, J. R., Javier Meana, J., Callado, L. F., Madrigal, J. L. M., García-Bueno, B., & Leza, J. C.
Affiliations
  • Universidad Complutense de Madrid (ES)
  • University of the Basque Country (ES)
Corresponding author
Caso, Javier R.
Venue
Journal of Neuroinflammation
Published
2018-09-04
Volume
15
Issue
1
Pages
251-251
ISSN
1742-2094 (ISSN-L)
OpenAlex
W2891464809
Cited by
80
References
74
Citations by year
2026: 8 · 2025: 7 · 2024: 8 · 2023: 15 · 2022: 9 · 2021: 17 · 2020: 9 · 2019: 5 · 2018: 2
FWCI
2.61
Type
journal article
Language
en
Open access
Licence
  • cc-by
  • creativecommons.org/licenses/by/4.0/ (tdm)
Locations
  • Journal of Neuroinflammation (publishedVersion, cc-by)
  • Europe PMC (PubMed Central) (publishedVersion, other-oa)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • Communities in ADDI (Universidad del Pais Vasco) (submittedVersion, other-oa)
  • Communities in ADDI (University of the Basque Country) (submittedVersion, other-oa)
  • LA Referencia (Red Federada de Repositorios Institucionales de Publicaciones Científicas) (submittedVersion, cc-by)
  • LA Referencia (Red Federada de Repositorios Institucionales de Publicaciones Científicas) (submittedVersion, other-oa)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
  • Hispana (submittedVersion, cc-by)
Funders
  • Instituto de Salud Carlos III (PI13/01102)
  • Gobierno Vasco (IT-616-13)
  • Centro de Investigación Biomédica en Red de Salud Mental
  • Secretaría de Estado de Investigación, Desarrollo e Innovación (RYC2015-17065, RYC2011-07955)
  • Ministerio de Economía, Industria y Competitividad, Gobierno de España (SAF2016-75500-R, SAF2017-83053-R)
Topics
  • Life Sciences › Neuroscience › Biological Psychiatry › Tryptophan and brain disorders
  • Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
  • Life Sciences › Neuroscience › Behavioral Neuroscience › Stress Responses and Cortisol
Keywords
major depressive disorder, TLR4, neuroinflammation, oxidative stress, nitrosative stress, HSP70, HSP60, MAPK signaling, p38 MAPK, JNK, DUSP2, Nrf2, antioxidant pathways, antidepressants, p11, dorsolateral prefrontal cortex, postmortem brain
MeSH terms
S100 Calcium Binding Protein A10, Analysis of Variance, Antidepressive Agents, Antioxidants, Autopsy, Major Depressive Disorder, DNA-Binding Proteins, Frontal Lobe, Humans, Inflammation, S100 Proteins, Transcription Factors, Signal Transduction, NF-kappa B, Annexin A2, Chaperonin 60, p38 Mitogen-Activated Protein Kinases, Toll-Like Receptor 4

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Intracellular inflammatory and antioxidant pathways in postmortem frontal cortex of subjects with major depression: effect of antidepressants. https://app.cochat.ai/papers/10.1186/s12974-018-1294-2
The paper
Martín-Hernández, D., Caso, J. R., Javier Meana, J., Callado, L. F., Madrigal, J. L. M., García-Bueno, B., & Leza, J. C. (2018). Intracellular inflammatory and antioxidant pathways in postmortem frontal cortex of subjects with major depression: effect of antidepressants. Journal of Neuroinflammation. https://doi.org/10.1186/s12974-018-1294-2

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.